NI201600051A - Combinaciones de inhibidores de histona desacetilasa y farmacos inmunomoduladores - Google Patents
Combinaciones de inhibidores de histona desacetilasa y farmacos inmunomoduladoresInfo
- Publication number
- NI201600051A NI201600051A NI201600051A NI201600051A NI201600051A NI 201600051 A NI201600051 A NI 201600051A NI 201600051 A NI201600051 A NI 201600051A NI 201600051 A NI201600051 A NI 201600051A NI 201600051 A NI201600051 A NI 201600051A
- Authority
- NI
- Nicaragua
- Prior art keywords
- combinations
- desacetilase
- histone
- inhibitors
- subject
- Prior art date
Links
- 229940124622 immune-modulator drug Drugs 0.000 title abstract 2
- 108010033040 Histones Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 208000034578 Multiple myelomas Diseases 0.000 abstract 2
- 206010035226 Plasma cell myeloma Diseases 0.000 abstract 2
- 229940121363 anti-inflammatory agent Drugs 0.000 abstract 1
- 239000002260 anti-inflammatory agent Substances 0.000 abstract 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 abstract 1
- 229960003957 dexamethasone Drugs 0.000 abstract 1
- 229940121372 histone deacetylase inhibitor Drugs 0.000 abstract 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361889640P | 2013-10-11 | 2013-10-11 | |
| US201361911089P | 2013-12-03 | 2013-12-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NI201600051A true NI201600051A (es) | 2017-07-11 |
Family
ID=52810182
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NI201600051A NI201600051A (es) | 2013-10-11 | 2016-04-11 | Combinaciones de inhibidores de histona desacetilasa y farmacos inmunomoduladores |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20150105358A1 (enExample) |
| EP (1) | EP3054939A4 (enExample) |
| JP (4) | JP2016532667A (enExample) |
| KR (1) | KR20160060143A (enExample) |
| CN (1) | CN105722507A (enExample) |
| AU (1) | AU2014332147A1 (enExample) |
| CA (1) | CA2926808A1 (enExample) |
| CL (1) | CL2016000838A1 (enExample) |
| CR (1) | CR20160200A (enExample) |
| EA (1) | EA201690753A1 (enExample) |
| IL (1) | IL244923A0 (enExample) |
| MX (1) | MX2016004604A (enExample) |
| NI (1) | NI201600051A (enExample) |
| PE (1) | PE20161342A1 (enExample) |
| PH (1) | PH12016500649A1 (enExample) |
| SG (1) | SG11201602791RA (enExample) |
| WO (1) | WO2015054175A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201735926A (zh) | 2010-01-22 | 2017-10-16 | 艾斯特隆製藥公司 | 作為蛋白質去乙醯酶抑制劑之反式醯胺化合物及其使用方法 |
| US8614223B2 (en) | 2010-11-16 | 2013-12-24 | Acetylon Pharmaceuticals, Inc. | Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof |
| EP2839037B1 (en) | 2012-04-19 | 2018-12-26 | Acetylon Pharmaceuticals, Inc. | Biomarkers to identify patients that will respond to treatment and treating such patients |
| US9145412B2 (en) | 2012-11-02 | 2015-09-29 | Acetylon Pharmaceuticals, Inc. | Selective HDAC1 and HDAC2 inhibitors |
| EP3054952B1 (en) * | 2013-10-08 | 2022-10-26 | Acetylon Pharmaceuticals, Inc. | Combinations of histone deacetylase 6 inhibitors and the her2 inhibitor lapatinib for use in the treatment of breast cancer |
| WO2015054474A1 (en) * | 2013-10-10 | 2015-04-16 | Acetylon Pharmaceuticals, Inc. | Pyrimidine hydroxy amide compounds as histone deacetylase inhibitors |
| KR20160060143A (ko) * | 2013-10-11 | 2016-05-27 | 에이스틸론 파마수티컬스 인코포레이티드 | 히스톤 디아세틸라아제 억제제와 면역조절성 약물의 조합물 |
| US10660890B2 (en) | 2013-10-24 | 2020-05-26 | National Institutes Of Health (Nih), U.S. Dept. Of Health And Human Services (Dhhs), U.S. Government Nih Division Of Extramural Inventions And Technology Resources (Deitr) | Treatment of polycystic diseases with an HDAC6 inhibitor |
| US9949972B2 (en) | 2013-12-03 | 2018-04-24 | Acetylon Pharmaceuticals, Inc | Combinations of histone deacetylase inhibitors and immunomodulatory drugs |
| US9464073B2 (en) | 2014-02-26 | 2016-10-11 | Acetylon Pharmaceuticals, Inc. | Pyrimidine hydroxy amide compounds as HDAC6 selective inhibitors |
| CN107205988A (zh) | 2014-07-07 | 2017-09-26 | 埃斯泰隆制药公司 | 利用组蛋白脱乙酰酶抑制剂治疗白血病 |
| JP2017537164A (ja) | 2014-12-05 | 2017-12-14 | ユニヴァーシティ・オブ・モデナ・アンド・レッジョ・エミリア | リンパ腫の治療に使用されるヒストン脱アセチル化酵素阻害剤とベンダムスチンとの組み合わせ |
| ES2816641T3 (es) | 2014-12-12 | 2021-04-05 | Regenacy Pharmaceuticals Inc | Derivados de piperidina en calidad de inhibidores de HDAC1/2 |
| TWI706937B (zh) | 2015-06-08 | 2020-10-11 | 美商艾斯特隆製藥公司 | 製備蛋白質去乙醯酶抑制劑之方法 |
| TW201718516A (zh) | 2015-06-08 | 2017-06-01 | 艾斯特隆製藥公司 | 組蛋白去乙醯酶抑制劑之晶形 |
| US11311540B2 (en) * | 2016-02-17 | 2022-04-26 | Acetylon Pharmaceuticals, Inc. | Increasing expression of interferon regulated genes with combinations of histone deacetylase inhibitors and immunomodulatory drugs |
| US11813261B2 (en) | 2016-04-19 | 2023-11-14 | Acetylon Pharmaceuticals, Inc. | HDAC inhibitors, alone or in combination with BTK inhibitors, for treating chronic lymphocytic leukemia |
| EP3468559B1 (en) | 2016-06-09 | 2023-11-22 | Dana Farber Cancer Institute, Inc. | Methods of use and pharmaceutical combinations of hdac inhibitors with bet inhibitors |
| US11324744B2 (en) | 2016-08-08 | 2022-05-10 | Acetylon Pharmaceuticals Inc. | Methods of use and pharmaceutical combinations of histone deacetylase inhibitors and CD20 inhibitory antibodies |
| KR102002581B1 (ko) * | 2016-10-04 | 2019-07-22 | 주식회사 종근당 | 혈액암 치료를 위한 hdac 저해제 및 프로테아좀 억제제 또는 면역조절성 약물을 포함하는 약학적 조합물 |
| WO2018098168A1 (en) * | 2016-11-23 | 2018-05-31 | Acetylon Pharmaceuticals, Inc. | Pharmaceutical combinations comprising a histone deacetylase inhibitor and a programmed death-ligand 1 (pd-l1) inhibitor and methods of use thereof |
| JP7516047B2 (ja) * | 2016-11-23 | 2024-07-16 | アセチロン ファーマシューティカルズ インコーポレイテッド | ヒストン脱アセチル化酵素阻害剤とｃｄ３８阻害剤とを含む医薬組み合わせ物及びその使用方法 |
| AU2020407664A1 (en) | 2019-12-20 | 2022-08-18 | Tenaya Therapeutics, Inc. | Fluoroalkyl-oxadiazoles and uses thereof |
| IL307883A (en) | 2021-04-23 | 2023-12-01 | Tenaya Therapeutics Inc | HDAC6 inhibitors for use in the treatment of dilated myocardial disease |
| EP4333841A1 (en) | 2021-05-04 | 2024-03-13 | Tenaya Therapeutics, Inc. | 2-fluoroalkyl-1,3,4-oxadiazol-5-yl-thiazol, hdac6 inhibitors for use in the treatment of metabolic disease and hfpef |
| WO2025215092A1 (en) | 2024-04-10 | 2025-10-16 | Institut National de la Santé et de la Recherche Médicale | Selective hdac6 inhibitors for use in the treatment of myotonic dystrophy type 1 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6281230B1 (en) | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
| US5635517B1 (en) | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
| US7968569B2 (en) * | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| US7323479B2 (en) * | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
| AU2006313517B2 (en) * | 2005-11-10 | 2013-06-27 | Topotarget Uk Limited | Histone deacetylase (HDAC) inhibitors (PXD101) for the treatment of cancer alone or in combination with chemotherapeutic agent |
| TW201735926A (zh) * | 2010-01-22 | 2017-10-16 | 艾斯特隆製藥公司 | 作為蛋白質去乙醯酶抑制劑之反式醯胺化合物及其使用方法 |
| US8614223B2 (en) * | 2010-11-16 | 2013-12-24 | Acetylon Pharmaceuticals, Inc. | Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof |
| US9512083B2 (en) | 2011-07-20 | 2016-12-06 | The General Hospital Corporation | Histone deacetylase 6 selective inhibitors for the treatment of bone disease |
| KR20160060143A (ko) * | 2013-10-11 | 2016-05-27 | 에이스틸론 파마수티컬스 인코포레이티드 | 히스톤 디아세틸라아제 억제제와 면역조절성 약물의 조합물 |
-
2014
- 2014-10-07 KR KR1020167011860A patent/KR20160060143A/ko not_active Withdrawn
- 2014-10-07 US US14/508,072 patent/US20150105358A1/en not_active Abandoned
- 2014-10-07 CR CR20160200A patent/CR20160200A/es unknown
- 2014-10-07 WO PCT/US2014/059387 patent/WO2015054175A1/en not_active Ceased
- 2014-10-07 CN CN201480062094.3A patent/CN105722507A/zh active Pending
- 2014-10-07 EA EA201690753A patent/EA201690753A1/ru unknown
- 2014-10-07 PE PE2016000490A patent/PE20161342A1/es not_active Application Discontinuation
- 2014-10-07 CA CA2926808A patent/CA2926808A1/en not_active Abandoned
- 2014-10-07 SG SG11201602791RA patent/SG11201602791RA/en unknown
- 2014-10-07 EP EP14851888.9A patent/EP3054939A4/en not_active Withdrawn
- 2014-10-07 AU AU2014332147A patent/AU2014332147A1/en not_active Abandoned
- 2014-10-07 JP JP2016521758A patent/JP2016532667A/ja active Pending
- 2014-10-07 MX MX2016004604A patent/MX2016004604A/es unknown
-
2016
- 2016-04-05 IL IL244923A patent/IL244923A0/en unknown
- 2016-04-08 PH PH12016500649A patent/PH12016500649A1/en unknown
- 2016-04-11 CL CL2016000838A patent/CL2016000838A1/es unknown
- 2016-04-11 NI NI201600051A patent/NI201600051A/es unknown
-
2018
- 2018-11-30 JP JP2018225287A patent/JP7403950B2/ja active Active
-
2019
- 2019-11-15 US US16/684,809 patent/US20200323849A1/en not_active Abandoned
-
2021
- 2021-02-12 JP JP2021020680A patent/JP2021073314A/ja active Pending
-
2023
- 2023-10-26 JP JP2023184173A patent/JP2024010118A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20150105358A1 (en) | 2015-04-16 |
| JP2024010118A (ja) | 2024-01-23 |
| JP2019052171A (ja) | 2019-04-04 |
| US20200323849A1 (en) | 2020-10-15 |
| JP2021073314A (ja) | 2021-05-13 |
| EA201690753A1 (ru) | 2016-07-29 |
| CA2926808A1 (en) | 2015-04-16 |
| CN105722507A (zh) | 2016-06-29 |
| SG11201602791RA (en) | 2016-05-30 |
| EP3054939A4 (en) | 2017-12-13 |
| JP7403950B2 (ja) | 2023-12-25 |
| CL2016000838A1 (es) | 2016-11-25 |
| KR20160060143A (ko) | 2016-05-27 |
| IL244923A0 (en) | 2016-05-31 |
| PH12016500649A1 (en) | 2016-05-30 |
| WO2015054175A1 (en) | 2015-04-16 |
| PE20161342A1 (es) | 2016-12-31 |
| EP3054939A1 (en) | 2016-08-17 |
| JP2016532667A (ja) | 2016-10-20 |
| AU2014332147A1 (en) | 2016-05-05 |
| MX2016004604A (es) | 2016-08-01 |
| CR20160200A (es) | 2016-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NI201600051A (es) | Combinaciones de inhibidores de histona desacetilasa y farmacos inmunomoduladores | |
| CR20160308A (es) | Combinaciones de inhibidores de histona deacetilasa y farmacos inmunomoduladores | |
| NI201600071A (es) | Compuestos de inhibidor de autotaxina | |
| ECSP18040250A (es) | Composiciones y métodos para inhibir la actividad arginasa | |
| CO2017004525A2 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
| MX393610B (es) | Terapia de combinacion que incluye un inhibidor mdm2 y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres | |
| MX2018005829A (es) | Composiciones para tratar el cabello. | |
| MX383484B (es) | Método para tratar el cáncer. | |
| MX2017000307A (es) | Tratamiento de leucemia con inhibidores de histona deacetilasa. | |
| MX2017000450A (es) | Compuestos terapeuticos inhibidores. | |
| HN2012000023A (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
| MX2015016100A (es) | Inhibidores de criopirina para prevenir y tratar la inflamacion. | |
| MX2017005861A (es) | Metodos para el control transcripcional objetivo en regiones del super mejorador. | |
| EA201690039A1 (ru) | Ингибиторы rorc2 и способы их применения | |
| NI201600070A (es) | Inhibidores tetracíclicos de autotaxina | |
| BR112017000730B8 (pt) | Derivados de pirrolidinona como inibidores de metap-2, e medicamentos | |
| MX2016015437A (es) | Combinacion que comprende un glucocorticoide y edo-s101. | |
| MX394452B (es) | Inhibicion de la actividad de olig2. | |
| UY35328A (es) | Tratamiento de formas progresivas de esclerosis múltiple con laquinimod | |
| BR112018003836A2 (pt) | combinações de inibidor de btk para tratar mieloma múltiplo | |
| MX2016011025A (es) | Composiciones de grapiprant y metodos para usar las mismas. | |
| MX2015012455A (es) | Metodo para el tratamiento de la enfermedad de higado graso. | |
| AR102871A1 (es) | Métodos de tratamiento de fibrosis | |
| MX381429B (es) | Tricostatina a (tsa) para usarse en el tratamiento del cáncer. | |
| AR103636A1 (es) | Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol |